Apparent Treatment-Resistant Hypertension Common in CKD
Most patients with CKD and apparent treatment-resistant hypertension had uncontrolled resistant hypertension or refractory hypertension.
Chronic Kidney Disease
Remdesivir Safe Despite Advanced CKD, Study Finds
Remdesivir is not currently recommended for use in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2.
Kerendia Label Updated With CV Outcomes Data From the FIGARO-DKD Study
Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%.
Estimated GFR Dip With Dapagliflozin Not Linked to Higher CKD Progression Risk
Understanding clinical characteristics associated with a decline in eGFR can help guide optimal use of SGLT2 inhibitors in clinical practice, according to investigators.
Patiromer Effective for Hyperkalemia Across CKD Stages
Patiromer was well tolerated in patients with nondialysis-dependent chronic kidney disease stages 1 to 5.
Study: Women Less Likely to Receive Appropriate CKD Care
Even women meeting objective criteria for CKD and nephrology referral were disadvantaged, according to investigators.
Higher Fluoroquinolone Doses May Be Toxic in Advanced CKD
Guidelines recommend that clinicians prescribe fluoroquinolone at lower doses in patients with reduced kidney function.
Substantial Discrepancies Found in Estimated vs Measured GFR in Individuals
New findings raise questions about the reliability of estimated glomerular filtration rate as a basis for clinical decision-making.
SGLT2 Inhibitors, MRA Compared for Diabetic Kidney Disease
Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.
Rosuvastatin Increases Risk of Hematuria, Proteinuria
Few real-world studies have investigated the risks of hematuria and proteinuria associated with rosuvastatin use.
